文献速递妇科

塔姆妥单抗帕莫齐林(SC-003)治疗铂耐药/难治性卵巢癌患者的1期研究结果

Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
PubMed 文献 · Gynecol Oncol · 2020-06-06

该首次人体1a/1b期研究评估了靶向DPEP3的抗体偶联药物SC-003单用或联合布迪利单抗(budigalimab)治疗铂耐药/难治性上皮性卵巢癌的安全性和抗肿瘤活性。74例患者接受SC-003治疗,最大耐受剂量为0.3 mg/kg(每3周方案),总体缓解率低(4%)且不持久,SC-003缺乏进一步开发所需的安全性和抗肿瘤活性。

要点

  • SC-003每3周方案的最大耐受剂量为0.3 mg/kg
  • 总体缓解率低(4%),且缓解不持久
  • SC-003缺乏进一步开发所需的安全性和抗肿瘤活性

核心结论

  • SC-003缺乏进一步开发所需的安全性和抗肿瘤活性。

研究设计与样本

  • 首次人体1a/1b期研究(NCT02539719),采用标准3+3设计,剂量限制性毒性观察期为21天。
  • 患者接受SC-003每3周一次,共6个剂量水平(0.025-0.4 mg/kg)。
  • 共纳入74例患者(剂量递增29例,剂量扩展45例,布迪利单抗联合组3例),均接受至少1剂研究药物。
  • DPEP3阳性肿瘤患者进入剂量扩展阶段,接受SC-003单药或联合布迪利单抗治疗。

主要发现

  • 发生1例剂量限制性毒性(3级肠梗阻),但被认为与研究药物无关。
  • 每3周方案的最大耐受剂量为0.3 mg/kg,剂量扩展阶段选择的SC-003剂量为0.3 mg/kg和0.2 mg/kg。
  • 最常见的治疗中出现的不良事件为疲劳、恶心、食欲下降、胸腔积液、腹痛和外周水肿。
  • 总体缓解率低(4%),且缓解不持久。
  • 事后分析提示DPEP3表达较高的患者缓解率较高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Epithelial ovarian carcinoma (EOC) is diagnosed at advanced stage in the majority of women and, despite being initially chemosensitive, eventually recurs and develops resistance to known therapies. SC-003 is a pyrrolobenzodiazepine-based antibody-drug conjugate targeting dipeptidase 3 (DPEP3), a membrane-bound dipeptidase associated with tumor-initiating cells in patient-derived EOC xenograft models. This first-in-human phase 1a/1b study evaluated the safety/tolerability, pharmacokinetics, and preliminary antitumor activity of SC-003 alone or in combination with budigalimab (formerly ABBV-181), an antibody targeting PD-1, in patients with platinum-resistant/refractory EOC (NCT02539719). METHODS: Patients received SC-003 at 1 of 6 dose levels (0.025-0.4 mg/kg) every 3 weeks (Q3W), utilizing a standard 3 + 3 design (dose-limiting toxicity [DLT] period: 21 days). Patients with DPEP3-positive tumors were enrolled in the dose-expansion phase of the study and treated with SC-003 monotherapy or in combination with budigalimab. RESULTS: Seventy-four patients (n = 29, dose escalation; n = 45, dose expansion; n = 3 budigalimab combination) were enrolled and received ≥1 dose of study drug. One DLT occurred (grade 3 ileus) but was considered unrelated to study drug. The MTD for the Q3W schedule was 0.3 mg/kg and the SC-003 doses selected for the dose-expansion phase of the study were 0.3 mg/kg and 0.2 mg/kg. The most common treatment-emergent adverse events were fatigue, nausea, decreased appetite, pleural effusion, abdominal pain, and peripheral edema. The overall response rate was low (4%), and responses were not durable. Post-hoc examination of antitumor activity suggested a higher response rate in patients with higher DPEP3 expression. CONCLUSIONS: SC-003 lacked the requisite safety profile and antitumor activity to warrant further development.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hamilton E, O'Malley DM, O'Cearbhaill R, et al. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020. PMID: 32513564. doi:10.1016/j.ygyno.2020.05.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。